John Bartlett
- Molecular Medicine top 0.1%
- Antibiotic Resistance in Bacteria 3
- Virology top 1%
- HIV Research and Treatment 5
- Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment 9
- HIV/AIDS Research and Interventions 8
- Microbiology top 0.5%
-
- HIV-related health complications and treatments 6
-
- Hepatitis C virus research 6
-
- Pneumocystis jirovecii pneumonia detection and treatment 4
-
- Systemic Lupus Erythematosus Research 3
- Co-authors
- David N. GilbertBrad SpellbergJohn E. EdwardsGeorge H. TalbotMichael ScheldHelen W. BoucherLouis B. RiceJohn S. Bradley
- Journals
- Clinical Infectious Diseases (5 papers)New England Journal of Medicine (2 papers)The Journal of Infectious Diseases (2 papers)
- Partner nations
- United StatesSwitzerlandTanzania
In The Last Decade
John Bartlett
38 papers receiving 5.8k citations
Hit Papers
Peers
Comparison fields: 5 of 155
- Molecular Medicine 2.2k
- Applied Microbiology and Biotechnology 793
- Virology 595
- Infectious Diseases 1.8k
- Microbiology 491
Countries citing papers authored by John Bartlett
This map shows the geographic impact of John Bartlett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Bartlett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Bartlett more than expected).
Fields of papers citing papers by John Bartlett
This network shows the impact of papers produced by John Bartlett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Bartlett. The network helps show where John Bartlett may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John Bartlett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 1 | |
| 2 | 2015 | 80 | |
| 3 | 2011 | 1 | |
| 4 | Absolute CD4 versus CD4 percentage for predicting the risk of opportunistic illness in HIV infection | 2004 | 0 |
| 5 | Treatment for adult HIV infection: 2004 recommendations of the international AIDS society-USA panel | 2004 | 17 |
| 6 | Peginterferon alfa-2a Plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-Co-infected persons | 2004 | 6 |
| 7 | The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for helicobacter pylori infections | 2004 | 19 |
| 8 | Clinical, virologic, and immunologic response to efavirenz- or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study) | 2004 | 0 |
| 9 | Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12-year cohort study | 2004 | 11 |
| 10 | Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: A 48-week randomized clinical trial | 2004 | 1 |
| 11 | Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients | 2004 | 1 |
| 12 | Weight loss and wasting in patients infected with human immunodeficiency virus | 2004 | 1 |
| 13 | CDC/HRSA/NIH/HIVMA of the IDSA recommendations for incorporating HIV prevention into the medical care of HIV-infected persons | 2004 | 1 |
| 14 | No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomized, double-blind, placebo-controlled trial | 2004 | 6 |
| 15 | Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine | 2004 | 1 |
| 16 | Persistent colonization by haemophilus influenzae in chronic obstructive pulmonary disease | 2004 | 20 |
| 17 | Updated guidelines for use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors | 2004 | 18 |
| 18 | Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: A randomized trial | 2004 | 2 |
| 19 | 2003 | 37 | |
| 20 | 2000 | 15 |
About John Bartlett
John Bartlett is a scholar working on Virology, Infectious Diseases and Emergency Medicine, having authored 40 papers that have together received 6.1k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (9 papers), HIV/AIDS Research and Interventions (8 papers), HIV-related health complications and treatments (6 papers), Hepatitis C virus research (6 papers), HIV Research and Treatment (5 papers), Pneumocystis jirovecii pneumonia detection and treatment (4 papers), Systemic Lupus Erythematosus Research (3 papers) and Antibiotic Resistance in Bacteria (3 papers). The work is most often cited by research in Molecular Medicine (2.2k citations), Applied Microbiology and Biotechnology (793 citations) and Virology (595 citations). John Bartlett has collaborated with scholars based in United States, Switzerland and Tanzania. Frequent co-authors include David N. Gilbert, Brad Spellberg, John E. Edwards, George H. Talbot, Michael Scheld, Helen W. Boucher, Louis B. Rice, John S. Bradley, Richard C. Reichman and Newton E. Hyslop. Their work appears in journals such as Clinical Infectious Diseases, New England Journal of Medicine, The Journal of Infectious Diseases, Patient Preference and Adherence and JAMA.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.